Items tagged with Diagnostics

TAG policy brief: Advancing Access through Market Interventions (post with simple image)

Lessons Learned from the GeneXpert Tuberculosis Test Buy-Down

TAG's 2020 Pipeline Report: TB chapters released (post with simple image)

Treatment Action Group (TAG) launches newly available TB chapters of its 2020 Pipeline Report.

Advocates request Cepheid increase access to GeneXpert SARS-CoV-2 tests in LMICs (post with simple image)

Advocates demand Cepheid commit a greater proportion of its COVID-19 manufacturing capacity to LMICs and lower the price of its cartridges to $5.

TB testing in 2020 dropped drastically due to COVID-19 (post with simple image)

Global Fund surveys in 13 countries with the highest TB burden in the world reveal that 29% fewer people were tested for TB compared to 2019.

Time for $5 Coalition statement: Cepheid’s updated GeneXpert pricing does not address country needs (post with simple image)

The Time for $5 Coalition calls out Cepheid for not including price reductions of Xpert tests in their updated GeneXpert pricing packages for low- and middle-income countries.

New WHO recommendations issued to improve access to rapid molecular tests for the detection of TB and drug-resistant TB (post with simple image)

WHO releases an update to its consolidated guidelines on the detection of TB and drug-resistant TB, accompanied by an operational handbook to facilitate rapid implementation and roll out of rapid molecular tests.

Substantial public investments in GeneXpert underscore need for affordable pricing (post with simple image)

PLOS ONE publishes TAG’s comprehensive analysis of public investments in the development of rapid technology for diagnosing infectious diseases.

Advocates ring the alarm on TB medicines and diagnostics stock outs across India (post with simple image)

Civil society networks in India call for the Ministry of Health and Family Welfare and the National TB Elimination Program to take urgent action.

Advocates urge Cepheid to reinstate plans to commercialize GeneXpert Omni (post with simple image)

Advocates call out Cepheid for canceling commercialization of the portable point-of-care GeneXpert Omni testing instrument and urge the company to reinstate plans to launch Omni, reiterating demands for Cepheid to reduce the price of GeneXpert tests to $5, inclusive of service and maintenance, across diseases.

TAG's 2021 Pipeline Report: TB chapters released (post with simple image)

Treatment Action Group (TAG) launches newly available TB chapters of its 2021 Pipeline Report.

Page 56 of 57 · Total posts: 0

←First 55 56 57 Last→